RXRX RECURSION PHARMACEUTICALS INC

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place earlier this morning, rather than coming up later this afternoon as previously stated. The corrected bullet should have read:

  • L(earnings) Call: We will host a L(earnings) Call on Aug 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time. We will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts and there will be opportunities to ask questions of the company.

The rest of the release remains unchanged.

Media Contact

Investor Contact



EN
08/08/2024

Underlying

RXRXRECURSION PHARMACEUTICALS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RECURSION PHARMACEUTICALS INC

 PRESS RELEASE
Free
RXRX RECURSION PHARM...

Recursion Announces FDA Clearance of Investigational New Drug Applicat...

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 monthsPlan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphoma SALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a le...

October 2, 2024 1 EN
 PRESS RELEASE
Free
RXRX RECURSION PHARM...

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Invest...

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically ...

September 3, 2024 1 EN
 PRESS RELEASE
Free
RXRX RECURSION PHARM...

CORRECTION - Recursion Provides Business Updates and Reports Second Qu...

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place earlier this morning, rather than coming up later this afternoon as previously stated. The corrected bullet should have read: L(earnings) Call: We will host a L(earnings) Call on Aug 8, 2024 at 8:...

August 8, 2024 1 EN
 PRESS RELEASE
Free
RXRX RECURSION PHARM...

Recursion and Exscientia Enter Definitive Agreement to Create a Global...

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities Operational complementarities expected to yield annual synergies of approximately $100 million Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver ...

August 8, 2024 1 EN
 PRESS RELEASE
Free
RXRX RECURSION PHARM...

Recursion Provides Business Updates and Reports Second Quarter 2024 Fi...

Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results Recursion entered into a definitive agreement to combine with Exscientia to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilitiesRecursion expects 7 clinical trial readouts for itself over the next 18 months and approximately 10 clinical readouts collectively over the same time period as part of a combined company with ExscientiaThe first neuroscience phenomap under Recursion’s collaboration with Roche and Genentech has been optioned, triggering a $...

August 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch